NewsPrivate Equity02/06/2025
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
Carlyle Group →Bluebird bio announced completion of its acquisition by Carlyle and SK Capital on 2 June 2025. Its shares ceased public trading. David Meek became CEO. This completion follows the February agreement and May amended consideration, which are preserved as distinct earlier news events.